Company
Overview
Pronota is building a portfolio of diagnostic tests based on novel protein biomarkers we discover and develop using our world leading, proprietary, high-performance biomarker technologies. Our most advanced program is in the field of acute heart failure where we are currently developing next-generation tests to improve the diagnosis and treatment of patients coming to the emergency department with shortness of breath. We also have diagnostic development programs ongoing in sepsis, pre-eclampsia and ovarian cancer. In addition to our internal biomarker discovery efforts we also partner with third party pharmaceutical and diagnostic companies to identify and verify high value biomarkers with applications in drug and diagnostics development.